Chapter 18. Inflammatory Immune Activation in Heart Failure Patients: Therapeutic Implications

  1. Ronald Ross Watson1,2 and
  2. Douglas F. Larson3
  1. Mohammad Abraham Kazemizadeh Gol and
  2. Mohsen Araghi‒Niknam

Published Online: 15 APR 2008

DOI: 10.1002/9780470692325.ch18

Immune Dysfunction and Immunotherapy in Heart Disease

Immune Dysfunction and Immunotherapy in Heart Disease

How to Cite

Gol, M. A. K. and Araghi‒Niknam, M. (2007) Inflammatory Immune Activation in Heart Failure Patients: Therapeutic Implications, in Immune Dysfunction and Immunotherapy in Heart Disease (eds R. R. Watson and D. F. Larson), Blackwell Publishing Ltd, Oxford, UK. doi: 10.1002/9780470692325.ch18

Editor Information

  1. 1

    Department of Nutritional Sciences, The University of Arizona; and Sarver Heart Center, College of Medicine, The University of Arizona

  2. 2

    Division of Health Promotion Sciences, Mel and Enid Zuckerman Arizona College of Public Health, The University of Arizona Tucson, AZ USA

  3. 3

    Sarver Heart Center College of Medicine The University of Arizona Tucson, AZ USA

Publication History

  1. Published Online: 15 APR 2008
  2. Published Print: 30 AUG 2007

ISBN Information

Print ISBN: 9781405155687

Online ISBN: 9780470692325

SEARCH

Keywords:

  • immune activation;
  • heart failure;
  • heart problem;
  • immunologic activity;
  • cardiovascular drugs

Summary

This chapter contains section titled:

  • Introduction

  • Heart failure and the immune system

  • TNFα trial

  • Current cardiovascular drugs and the inflammatory response

  • Inflammatory activity of the serum in HF patients

  • Possible treatments

  • Conclusion

  • References